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Abstract 
Autism spectrum disorder (ASD) is a neurodevelopmental 
disorder characterized by impairment in social, behavior and 
communicative skills. The current therapy for ASD only 
targets the associated symptoms such as aggression, self-
harming acts or temper tantrums but not the core symptoms 
of social dysfunction. The pathology of ASD is not fully under-
stood. Interestingly, imaging studies in ASD patients have 
reported abnormal high levels of glutamate in certain brain 
regions that play an important role in social interaction and 
communication. Thus, it has been hypothesized that medica-
tions attenuating glutamate transmission may be used as treat-
ment for some of the core symptoms of ASD. Memantine, an 
N-methyl-D-aspartate (NMDA) receptor antagonist, has been 
approved for the treatment of Alzheimer's disease, and has 
shown promise in alleviating some of the symptoms of ASD in 
children. In this review, we will discuss the pathology of ASD, 
findings from studies that evaluated memantine in ASD pa-
tients, the adverse effects of memantine and the potential use 
of memantine in the treatment of ASD. Finally, we will discuss 
the role of the pharmacist in managing patients with ASD. 
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Introduction 
Autism spectrum disorder is a heterogeneous neurodevelop-
mental disordert characterized by core features including 
developmental delays in communication and social interac-
tion and repetitive behaviors and/or restricted interests.2 
Deficits in communication and social interaction manifest as 
shortfalls in "social-emotional reciprocity," nonverbal com-
munication and difficulty with relationships. In addition, 
patients with ASD show repetitive behaviors, interests, 
movements or atypical interests in sensory aspects of their 
environment. The full clinical diagnosis of ASD is defined by 
the diagnostic statistical manual-V (DSM-V). 
According to the Centers for Disease Control and Prevention 
(CDC), in 2012, about one in 68 children were identified with 
ASD.3 Interestingly, boys are about five times more likely to be 
diagnosed with ASD than girls. Screening for ASD is usually 
done at well-child doctor visits.4 If the physician/pedia-trician 
notices any abnormalities, such as the ones described above, a 
comprehensive diagnostic evaluation is performed, which 
includes a detailed evaluation of the child's behavior and de-
velopment and an interview with the parents. Diagnoses 
made by age 2 or older are considered very dependables, but 
ASD could possibly be identified before 18 months of age.4 
Currently, antipsychotic medications rispe1idone and ari-
piprazole are approved by the U.S. Food and Drug Administra-
tion (FDA) for the treatment of associated symptoms of ASD 
including aggression, self-harming acts and temper tantrums 
commonly seen in autistic patients between 5 and 16 years of 
age.6-7 There are currently no FDA approved medications that 
directly target the pathological mechanisms underlying au-
tism or treat the core symptoms of ASD described above. 
Recent studies, however, suggest abnormalities in glutamate 
transmission in autism that could possibly be a target for 
treatment. Glutamate is the primary fast-acting excitatory 
neurotransmitter within the central nervous system (CNS).s 
The actions of glutamate in the CNS are mediated by 
ionotropic receptors such as the a-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA), kainate and 
N-methyl-D-aspartate (NMDA) receptors.9 A few clinical 
studies have evaluated the effects of memantine, an antago-
nist of the NMDA glutamate receptor,9 in patients diagnosed 
with ASD. In this review, we will first discuss glutamate ab-
normalities in specific brain regions that have been reported 
in ASD patients. In addition, we will discuss findings from 
studies that evaluated memantine in ASD patients, the ad-
verse effects of memantine and the potential adverse effects 
of memantine in the treatment of ASD. Finally, the role of the 
pharmacist in managing ASD patients will be reviewed. 
Pathology in Autism Spectrum Disorder 
The etiology of ASD is not known, although research has 
shown that there is a strong hereditary influence accompa-
nied by genetic mutations.1 More than 20 different mutations 
have been identified. Also implicated are further epigenetic 
changes, which include modifications in gene expression that 
do not change the deoxyribonucleic acid (DNA) sequence. 
Overall, the genetic mutations and epigenetic changes affect 
proteins that are responsible for neuronal function, cell me-
tabolism, protein synthesis and gene expression. 
Irregularities in glutamate concentrations within the brain 
have been reported in ASD patients. Concentrations of gluta-
mate in the brain can be measured using proton magnetic 
resonance spectroscopy (1H MRS). In a study that utilized tH 
MRS, Brown et al. reported elevations in glutamate + gluta-
mine signal (Glx) in certain brain regions of ASD patients.to 
For example, the Glx in the auditory cortex was found to be 
significantly elevated in the ASD patients when compared to 
the control groups. It should be noted that the ASD patients 
(n=l3) were ages 25 to 48 years, and they were compared 
with healthy adults (n=15) and parents of ASD children not 
included in the study (n=15). In addition, Page and col-
leagues found that adults with ASD (n=20) had a significant 
increase in Glx in the amygdala-hippocampal complex 
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(P<0.05) compared to healthy patients (n=13J.n Using t H 
MRSI (proton magnetic resonance spectroscopic imaging), 
Bejjani et al. showed that children with ASD (n=26) had in-
creased Glx in the right pregenual anterior cingulate cortex 
(P<0.05) compared to typically developing children (n=16).12 
In contrast to the above described studies, some studies re-
port a decrease in Glx signal. For instance, Bernardi et al. 
found that the right anterior cingulate cortex had a de-
creased Glx signal in ASD adults (n=14, P<0.006) than in 
healthy controls (n=14).t3 One possible reason for the con-
trasting findings with respect to anterior cingulate cortex Glx 
signal and glutamate levels between the studies of Bernardi 
et al. and Bejjani et al. could be due to differences in age of 
subjects evaluated in the two studies. For example, subjects 
included in the study of Bernardi et al. were adults (age 
range 21 to SO years), while the subjects studied in Bejjani et 
al. were children (age range 6.1 to 17.S years). In addition, 
Horder et al. found that ASD patients had decreased Glx in 
the basal ganglia (P<0.0001).14 Overall, the imaging studies 
suggest that the direction of alteration in glutamate levels in 
ASD patients may be dependent on the age group of patients 
and the particular brain region studied. 
In addition to irregularities in glutamate levels described 
above, alterations in glutamate receptor mRNA expression or 
density have been reported in ASD patients. A postmortem 
study conducted by Purcell et al. examined brain samples 
from the cerebellar cortex of autistic patients (n=lO) and 
control patients (n=23), which were matched based upon age 
and gender.ts They reported a significant increase (P<0.05) 
in levels of AMPA 1, 2, 3 mRNA in the cerebellar samples of 
autistic subjects (n=lO) compared to control subjects (n=lO). 
Furthermore, increased levels of AMPA 1 (P<0.001) and 
NMDA receptor 1 (P<0.05) subunit proteins were reported in 
brain samples of autistic subjects (n=9) compared to controls 
(n=ll). However, despite elevations in the mRNA and pro-
tein levels of specific AMPA and NMDA receptor subunits, 
Purcell et al. reported decreased density of AMPA receptors 
in the granule (P<0.05) and molecular cell layer (P<0.01) of 
the cerebellum in samples of autistic subjects compared to 
control subjects using autoradiography. Interestingly, there 
was no difference in density of the NMDA receptors in the 
different layers of the cerebellum. In summary, the above 
evidence from molecular studies suggests elevation of gluta-
mate receptor expression (mRNA and protein) in specific 
brain regions in ASD patients. 
Binding of glutamate to the NMDA receptor allows the entry 
of calcium and sodium ions into the neuron.a This entry of 
calcium and sodium ions via opening of the NMDA receptors 
results in depolarization and activation of the neurons. How-
ever, excessive release of glutamate and activation of the 
NMDA receptors can result in excitotoxicity and loss of neu-
rons. Hence, it is hypothesized that attenuating glutamate 
transmission will have a neuroprotective effect and prevent 
loss of existing neurons. Consequently, memantine, a non-
competitive NMDA receptor antagonist,9 may provide the 
desired neuroprotective effects and promotion of neurogene· 
sis. Currently, memantine is approved by the FDA for 
moderate to severe dementia caused by Alzheimer's disease. 
Several studies have evaluated memantine in children with 
ASD. Because the DSM-V criteria for ASD were released only 
recently (May 2013), most of the studies described in this 
article have used the DSM-IV-TR criteria, which was the 
standard criteria at the time the studies were conducted. 
Clinical evaluation of Memantine in ASD 
In a retrospective observational study, Erickson et al. evalu· 
ated the effects of memantine on symptoms associated with 
autism, such as social withdrawal, communication impair-
ment, irritability and inattention/hyperactivity.16 The study 
included 18 patients (mean age of 11.4 years) who had more 
than one symptom and were treated at an outpatient treat-
ment center for autism. All patients were evaluated by psychi-
atrists and met the DSM-IV-TR criteria for autism. Patients 
began with either 2.Smg or Smg memantine daily depending 
on their weight, which was titrated up by either 2.Smg or Smg 
every two weeks to a maximum of 20mg daily or until a re-
sponse or side effects were observed. Thirteen patients were 
taking concurrent medications, mainly anticonvulsants, anti-
depressants or second-generation antipsychotics, which were 
maintained during the trial. Of those taking second-
generation antipsychotics, three patients were either on 
risperidone or aripiprazole, which are FDA approved medica-
tions for autism patients. A clinical global impressions-
severity subscale (CGl-S) and CG I-Improvement subscale (CGI 
-I) was completed at baseline and during clinic visits to docu-
ment changes in symptoms. The CGI-S was rated from 
1 to 7 (1-normal, 7-extremely ill) while the CGl-1 was also rat-
ed from 1 to 7 (1-very much improved, 7-very much worse). 
Patients with a CGI-1 rating of 1 or 2 after the trial were con-
sidered treatment responders. Only six patients had complet-
ed scores at baseline and post-trial conducted on the aberrant 
behavior checklist-community (ABC-C) irritability subscale, a 
58-item subscale used to assess disruptive behavior and de-
velopmental disabilities. The range of the study period was 
1.5 to 56 weeks (mean of 19.3 weeks) with a mean dose of 
10.lmg/day. The CGI-S scores showed a significant decrease 
from baseline (p<0.01) although the CGl-1 improvement was 
not substantial. Patients with CGl-I ratings of much improved 
(n=6) or very much improved (n=S) were considered as treat-
ment responders. For patients who did have ABC data, the 
only significant improvement was the hyperactivity subscale 
(p<0.05). Adverse effects occurred in seven of the patients 
and included irritability (n=4), rash (n=l), emesis (n=l), in-
creased seizure frequency (n=l) and excessive sedation 
(n=l). Two patients stopped treatment due to unresponsive-
ness, while four stopped treatment because of adverse effects. 
Overall, the results reflected the beneficial use of memantine, 
especially in improving social interaction and attention. There 
were, however, several limitations to this study. The sample 
size of the study was small, thus making it difficult to form 
true associations within this observational study. The length 
of the treatment for each patient was not addressed by the 
authors, which varied and may not have allowed enough time 
to determine the efficacy and side effects of memantine. 
Importantly, only five patients were on monotherapy with 
memantine during the study, indicating that the other 13 pa-
tients were taking other concurrent medications, which could 
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have influenced the data with their varying therapies. Lastly, 
ratings on the CGI scales were not made by the same physician 
for each patient, indicating that scores may have been affected 
by the subjective impressions of the different physicians. 
An open-label study by Chez et al. evaluated the efficacy of 
memantine in the treatment of language and social behavior-
al symptoms in patients diagnosed with autism.17 The study 
included 151 patients who were found eligible through dini-
cal observation and the DSM-IV criteria for autism (n=105) 
and pervasive developmental disorder not otherwise speci-
fied (POD-NOS; n=46). Pervasive developmental disorder is 
characterized by severe impairment in developing reciprocal 
social interaction due to impaired communication skills or 
behavior.is Patients were predominantly male (mean age of 
9.31 years). Those taking concurrent medications, which 
were primarily selective serotonin reuptake inhibitors, atypi-
cal antipsychotics, stimulants, alpha-adrenergic antagonists 
and cholinesterase inhibitors, were required to take them 
consistently for at least eight weeks before treatment and 
during the study. Of these patients, 31 were taking risperi-
done, while five were taking aripiprazole. Patients with Frag-
ile X or Rett syndrome genetic disorders, metabolic disorders 
or brain malformations were excluded from the study. The 
starting dose ofmemantine was 5mg/day, which was titrated 
up or down every four to six weeks in 2.5 or 5mg increments 
up to 30mg/day. Patient follow-up was carried out via 
phone calls or email every four weeks and clinical assess-
ments were conducted every eight to 12 weeks. The dura-
tion of the study had a range of one to 20 months 
(mean=9.27 months). Assessments of the treatment were 
conducted by a primary clinician and caretaker through in-
terviews, diaries, clinical examinations and observations. 
These were translated onto the CGl-1 seven-point scale for 
language by examining receptive skills and utterances, be-
havior through cognitive improvement in social interactions 
and self-stimulatory activity by observing the amount and 
type of patient activity. The CGI-1 for behavior was observed 
through social interaction, ability to cooperate at home and 
school and attentiveness to others. A score of either 1 or 2 
was considered to be significant improvement in all three 
categories. The CGI-I for language and behavior had a signifi-
cant improvement in about 70 percent of both autism and 
POD-NOS patients together, with changes occurring in the 
first two to four weeks. Improvement was also found to in-
crease as length of therapy increased. When excluding the 
POD-NOS patients, however, language improvement in au-
tism alone was not found to be significant More specifically, 
65/105 and 67 /105 autism patients were found to have rat-
ings of significant improvement in language and behavior 
respectively. When excluding those who stopped treatment, 
language improvement was still significant for both the autistic 
and POD-NOS patient groups, while behavioral improvement 
was not Lastly, for the CGl-1 for self-stimulatory stereotypic 
behaviors, only those observed with these behaviors at base-
line were included (n=l16). Only nine of the patients with 
autism were found to have significant improvement and 
there was found to be no progress in self-stimulatory behav-
ior and duration of treatment overall for both autism and 
POD-NOS patients. From the sample, 22 patients experienced 
worsening of symptoms and dropped out, while five patients 
stopped therapy because of a lack of response. Although ab-
normal electroencephalography findings were observed in 
patients, these changes were concluded to be normal for this 
patient population. For patients with concurrent therapy, 
hematological, serum chemistry and hepatic profiles were 
examined and found to have no changes. The results of the 
study seem to suggest that memantine is a safe adjunct thera-
py for patients with autism for improvement of language and 
behavioral symptoms. Importantly the study showed that 
memantine resulted in improvement of language and behav-
ioral symptoms in a majority of patients, although improve-
ments were not statistically significant when patients who 
withdrew from the study were excluded from the analysis. A 
major limitation of the study was that the researchers relied 
on CGI-1 subscale scores, which were not scored by the same 
clinician or caretakers, indicating possible subjectivity in rat-
ings, which may have affected the results. Furthermore, con-
current medications being taken by the patients were not the 
same for all the patients and may have influenced the results. 
Ghaleiha et al. examined the effects of memantine as an ad-
junct therapy with risperidone.19.zo Forty children between 
the ages of 4 and 12 years (mean age of 7.42 years), who met 
the diagnostic DSM IV-TR criteria for autism confirmed by a 
child psychologist, were included in the 10-week double-
blind randomized placebo-controlled trial. Inclusion criteria 
also comprised a screening and baseline ABC-C irritability 
subscale score of<:: 12. Children who had concomitant schizo-
phrenia, psychotic disorders, a history of drug or alcohol 
abuse, tardive dyskinesia, active clinical seizures, significant 
medical problems, had taken memantine previously or had 
taken an antipsychotic drug treatment six months before 
enrollment began were excluded from the study. Patients 
were randomized into two equal parallel groups, and an 
equal number of girls and boys were included in each group. 
One group received memantine and risperidone, while the 
other group received a placebo and risperidone. The starting 
dose of risperidone was 0.5mg tablet/day, which was gradu-
ally titrated up 0.5mg weekly to a maximum of 2mg/day for 
children weighing 10 to 40kg, and a maximum of 3mg/day 
for children weighing >40kg. Memantine doses started at 
5mg caplet/day and were titrated up or down in 5mg incre-
ments each week to a maximum of 15mg/day for children 
weighing 10 to 40kg and 20mg/day for children weighing 
>40kg. All drugs, including placebo, began at the same time 
and any psychosocial intervention therapy was stopped. The 
primary outcome was the irritability subscale measured by 
the ABC-C. This was used to evaluate five types of behavioral 
abnormalities, where three were core deficits (lethargy/ 
social withdrawal, stereotypic behavior, inappropriate 
speech) and two were associated disturbances (irritability, 
hyperactivity /noncompliance). Ratings on the ABC-C scale 
followed standardized instructions by a trained resident of 
psychiatry and the children's parents every two weeks. 
Scores at baseline were compared to scores during treatment 
weeks 2, 4, 6, 8, and 10 (end point). The extrapyramidal 
symptoms rating scale was also used to measure extrapy-
ramidal symptoms, such as tardive dyskinesia, akinesia, aka-
thisia and parkinsonism.21 Independent raters and a medical 
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student documented side effects every two weeks. All pa-
tients were able to complete the trial and none were lost to 
follow-up. The memantine treatment group showed a signifi-
cant difference in ratings when compared to the placebo in 
the ABC-C irritability, stereotypic behavior and hyperactivi-
ty /noncompliance subscales. No significant difference was 
observed in the lethargy/social withdrawal or inappropriate 
speech subscales. In addition, there were no significant dif-
ferences found between groups in extrapyramidal symptoms 
or the frequency of side effects, which included abdominal 
pain, changes in appetite, dizziness, insomnia, nausea, seda-
tion and rash. There were several limitations of the study. 
Primarily, the short trial duration of 10 weeks did not allow 
for an extended length of time to observe side effects, and/or 
efficacy of memantine in causing symptomatic improvement 
Furthermore, different scorers for the different subscales 
could have led to subjective variability in ratings, which 
could have influenced the data. Overall, the results of the trial 
indicated a positive effect of memantine on one core and two 
associated symptoms of autism. 
More recently, five clinical trials of memantine use in pediat-
ric patients with ASD were completed and Forest Pharma-
ceuticals submitted the results for review by the FDA in June 
2014.22 The complete trial details of these studies were una-
vailable at the time of writing this article. However, the FDA 
clinical review is available on its website and has provided 
some insight into the trials. Two of the five studies were re-
viewed for the efficacy of memantine in pediatric (ages 6 to 
12 years) ASD patients. Both studies were 12-week double-
blind placebo controlled trials with 114 patients in MD-57A 
and 471 patients in MD-68. The MD-S7A trial was a two-part 
trial. The first part of the trial was excluded from the clinical 
review because it was open-labeled. The second part of the 
trial consisted of patients who met DSM-IV specifications for 
autism according to the autism diagnostic observation sched-
ule (ADOS) and the autism diagnostic interview-revised 
(ADI-R). These patients were then placed on two weeks of 
single-blind placebo. By the end of the two weeks, if the pa-
tients still met the inclusion criteria, they were randomized 
to either placebo or weight-based flexible-fixed memantine 
doses (3 to 15mg) in a 1:1 ratio. The primary efficacy end-
point of the 12-week trial was the mean change from base-
line of the SRS (social responsiveness scale) scores at the end 
of the trial. According to the FDA clinical review, memantine 
did not show superiority to placebo treatment. The common 
adverse events observed in this trial were agitation, ear in-
fection, affective disorder, allergic rhinitis, influenza, lacera-
tion, enuresis and frequent bowel movements. 
Table 1. Memantine's dosage forms and prices.*2s 
Namenda: Tablets, oral 
Namenda Titration Pak: Tablets, oral 
Namenda XR : Capsules, extended release, oral 
Namenda XR Titration Pack Oral : Capsules, extended release, oral 
Namenda : Solution, oral 
* Costs without insurance coverage 
The MD-68 trial was a parallel group, multicenter, double-
blind, randomized, withdrawal study with 471 ASD patients 
between the ages of 6 and 12 years. In addition, these pa-
tients had already completed 12 weeks of open-label me-
mantine administration and had at least a 10 point decrease 
in the SRS total raw score in the MD-91 trial. Patients were 
then randomized in a 1:1:1 ratio with full dose memantine, 50 
percent memantine dose or placebo. According to the FDA 
clinical review, memantine did not demonstrate superiority to 
placebo. Also, the adverse events observed in the trial were of 
little clinical significance in the opinion of the clinical review-
er. Dose related adverse events were not observed, but the 
lead-in study may have affected these results. Based on these 
more recent studies, the FDA clinical review recommended 
approval of the memantine indication for adolescents/ 
children with autism despite lack of efficacy to treat the core 
symptoms of autism. Further scrutiny of the data and the FDA 
clinical review will only be possible when the complete stud-
ies are available for review to the larger clinical community. 
In summary, studies published to date in the literature as-
sessing memantine either as an adjunct therapy or mono-
therapy for the core symptoms of ASD had limitations either 
due to small sample size or study design. Therefore, these 
trials have limited external validity. Although all of these 
published studies suggested positive benefit using meman-
tine, further double-blind studies with robust sample sizes 
and study design will be required to determine the role of 
memantine in the treatment of ASD patients. Based on more 
recent studies, the data of which is available only to the FDA 
currently, the FDA clinical review has recommended approv-
al of memantine for treatment of ASD in adolescents/ 
children despite lack of clinical efficacy.22 However, Forest 
Pharmaceuticals, memantine's manufacturer, does not plan 
to seek a pediatric indication of memantine at this time. 
Pharmacist Role and Counseling Points 
Memantine is approved by the FDA to treat moderate-to-
severe Alzheimer's disease. Memantine is prescribed 
off-label for treatment of ASD as described above, and the 
pharmacist has a significant role in educating parents and 
patients about the therapeutic efficacy and adverse effects of 
memantine for this patient population.23 
Memantine is available in several dosage forms including 
tablets, capsules in extended release forms and a solution. 
The cost varies depending on the dosage forms and strengths 
(See Table 1). Namenda® titration packs are blister packages 
containing 49 tablets of 28 x Smg and 21x10mg. Namenda® 
5mg (60), IOmg (60) $374.99 
5mg (28), JO mg (21) $306.18 
7mg (30) $356.26 
14mg(90) $1068.74 
2 lmg(30) $356.26 
28mg(90) $1068.74 
7mg (7), l 4mg (7), 21 mg (7), 28mg (7) $332.5 1 
2mg/mL (360mL) $725.32 
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extended release titration packs are blister packages contain-
ing 28 capsules of 7 x 7mg, 7 x 14mg, 7 x 2 lmg and 7 x 28mg. 
The solution form may contain sorbitol, and capsules may 
contain sugar.24 0ral pediatric dosing adjustment is not yet 
established, but the clinical studies involving adolescents 
start with a low dose of 2.Smg daily or Smg daily, and titrate 
up to maximum of 15mg, 20mg or 30mg daily depending on 
the weight of the patientt6,11,19 
Memantine is well tolerated with low adverse events when it 
is used to treat dementia. In addition, no significant side ef-
fects were observed when the medication was given to 
adolescents for autism. Adverse reactions are similar to im-
mediate and extended release formulations. If the patient has 
hypersensitivity to memantine or any component of the .for-
mulation, the drug should not be used. Bupropion, carbonic 
anhydrase inhibitors, sodium bicarbonate and trimethoprim 
are known to interact with memantine. Memantine is a sub-
strate of organic cation transporter (OCT 2), and bupropion 
may increase the serum concentration of OCT 2 substrates. 
Carbonic anhydrase inhibitors and sodium bicarbonate may 
decrease the excretion of memantine with the exception of 
brinzolamide and dorzolamide. Trimethoprim may enhance 
the adverse and toxic effects, especially the risk of myoclonus 
and/or delirium. Therefore, these four drugs should be moni-
tored when memantine is given to patients. 2s 
The CDC has analyzed several alternative treatment options 
including behavior and communication approaches, dietary 
approaches and complementary and alternative medicine 
(CAM). One behavior and communication approach, known 
as applied behavior analysis (ABA), is a widely accepted 
treatment option to help children with ASD. The objective of 
ABA treatment is to encourage positive behaviors and dis-
courage negative behaviors so that patients can progress 
toward positive activities. Applied behavior analysis includes 
different types of treatment, and other therapies can be a 
part of a program (See Table 2). Dietary approaches are not 
recommended because treatments are based on the unprov-
en idea that some food or lack of vitamins and minerals may 
cause symptoms of autism. Removing certain types of foods 
may be harmful to a child, so refer to the physician if this 
treatment option is being considered. In addition, CAM is not 
recommended. Complementary and alternative medicine 
includes special diets, chelation (a treatment to remove 
heavy metals such as lead from the body) and body-based 
systems such as deep pressure. The efficacy of these treat-
ments are very controversial and may even cause dangerous 
consequences to a child's health. Therefore, patients should 
consult with their physician prior to implementing treat-
ment;.26 
Conclusion 
Currently, there are no medications to treat the core symp-
toms of autism such as communication and social deficits. 
The FDA approved medications for autism, namely risperi-
done and aripiprazole, treat related symptoms of aggression, 
self-harming acts or temper tantrums in children between 
Table 2. Description of Applied Behavior Analysis (ABA) and Other Therapies.26 
Broken down into smaller steps. 
ABA Discrete Trial Training (DTT) Rewards for positive behaviors and 
incorrect answers are ignored. 
Early Intensive Behavior Intervention ABA for younger children of usually 
(EIBI) younger than 5 or often younger than 3. 
Pivotal Response Training (PRT) Focus on communication and social 
skills. 
Verbal Behavior Intervention (VBI) Focus on verbal ski lls. 
Developmental, Individual Differences, Relationship-Based Approach Focus on emotional and relational development. Focus on how the child (DIR; "Floor time") 
reacts to sights, sounds and smells. 
Treatment and Education of Autistic and related Communication-handicapped Use visual aids such as picture cards. Children (TEACCH) 
Focus on the child's daily activities such 
Occupational Therapy as dressing, eating, bathing, and relating 
to people. Reinforce independence. 
Focus on sensory information to help a 
Sensory Integration Therapy child who is disturbed by sounds or 
touch. 
Speech Therapy Focus on communication skills. 
The Picture Exchange Communication System (PECS) Use picture symbols to improve 
communication skills. 
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the ages of 5 and 16 years. An FDA approved drug for treat-
ing Alzheimer's disease, memantine, has been suggested as a 
possible treatment option to treat the core symptoms of ASD. 
Imaging studies report increased glutamate levels in certain 
brain regions in ASD patients. Similarly, postmortem studies 
suggest increased mRNA levels of NMDA receptors in certain 
brain regions of ASD patients. Consistent with these findings, 
several published clinical studies reviewed here demonstrate 
possible benefits of using memantine, an NMDA antagonist. 
However, the studies published thus far are not very robust 
due to their small sample sizes and weak study designs. 
Based on studies still not available to the larger scientific 
community, the FDA clinical review has recently recom-
mended approval of memantine for use in ASD patients 
despite lack of efficacy. Pharmacists must undertake a signifi-
cant role in understanding memantine's use in ASD patients 
in light of unreliable efficacy, as well as in understanding oth-
er therapies widely utilized for ASD management 
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